DataMeds AI Inc. (NASDAQ:MEDS) surged 55.28% to $1.13 in after-hours trading Thursday after announcing a deal to acquire cancer diagnostics assets from the estate of Todos Medical Ltd., an Israeli in vitro diagnostics company. The stock had closed at $0.73.
According to a company announcement that was made after the markets closed on Thursday, DataMeds agreed to acquire Todos’ Cancer AI Total Biochemical Infrared Analysis (TBIA) blood tests. They include two breast cancer tests (TM-B1 and TM-B2) and one colorectal cancer test (TM-C1).
What the TBIA Platform Offers
The platform uses Fourier-transform infrared (FTIR) spectroscopy to analyze blood plasma. One blood draw can run multiple cancer algorithms, which the company says may cut per-test cost of goods sold (COGS). The release says U.S. and European patents provide market exclusivity into at least 2034.
The Florida-based health IT and healthcare company will also acquire Todos’ license to the LymPro Alzheimer’s blood test and its Singapore subsidiary.
"The TBIA Cancer AI blood testing platform is a technology that was ahead of its time," Interim Co-CEO Gerald Commissiong said in the release. He said earlier detection could support routine annual blood testing.
The company plans to run the work at its Helomics lab in Pittsburgh.
Risks Remain for MEDS Investors
The deal needs court approval. The company also said the TBIA tests are not Food and Drug Administration-cleared or approved and are not commercially available in the U.S.
Trading Metrics, Technical Analysis
DataMeds has a market capitalization of about $4.16 million. Over the past 52 weeks, its stock has traded as high as $12.31 and as low as $0.50.
MEDS has a Relative Strength Index (RSI) of 28.51.
Over the past 12 months, the small-cap stock has fallen 97.49%.
Price Action: In the regular session, MEDS closed at $0.73, down 1.53%, according to Benzinga Pro data.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: FabrikaSimf on Shutterstock.com
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.



